Biotech
Aliada Therapeutics
Aliada Therapeutics raises $1.4B Acquisition at $1.4B valuation
South San Francisco, CAOctober 25, 20241 min read
Total Raised
$1.4B
Valuation
$1.4B
Latest Round
Acquisition
Employees
90+
Aliada Therapeutics: Acquisition Funding Round
Aliada Therapeutics has successfully raised $1.4B in Acquisition funding, reaching a valuation of $1.4B.
Company Overview
Blood-brain barrier platform acquired by AbbVie for CNS therapies
Funding Details
The Acquisition round was led by AbbVie (acquirer).
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2018
- Employees: 90+
- Category: Biotech
Investment
Aliada Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- AbbVie (acquirer): Verified investor in Acquisition
Company Info
Headquarters
South San Francisco, CA
Founded
2018
Team Size
90+
Last Round
$1.4B(Oct 2024)
Investors (1)
A
AbbVie (acquirer)LeadLead Investor
Verified investor in Acquisition
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free